Skip to content
SEC EDGARcompany profilefree

AbbVie Inc. due diligence

Who AbbVie Inc. (ABBV) is on the public record: identity, annual results, what it filed in the last year and why, straight from SEC EDGAR.

1010 filings in EDGAR's recent index572 of them Form 4 filingsview the filings on SEC EDGARsource: SEC EDGAR, XBRL data

At a glance

AbbVie Inc. (ABBV) is a large accelerated filer incorporated in Delaware, classified under SIC 2834 (Pharmaceutical Preparations), and lists on NYSE. Its fiscal year ends December 31.

For the fiscal year ended December 31, 2025, its 10-K reported revenue of $61.2B, up 8.6% from the year before, net income of $4.2B, and total assets of $134B.

In the twelve months to November 21, 2026 it made 89 filings on EDGAR, including 1 annual report, 3 quarterly reports, 17 current reports on Form 8-K, and 44 Form 4 insider filings, plus 7 prospectus supplements and free writing prospectuses for its securities offerings. Its 8-Ks were filed most often for results of operations (8), other events (4), and officer or director changes (2).

CIK
0001551152
Filer status
Large accelerated filer
Industry (SIC)
Pharmaceutical Preparations (2834)
Incorporated
Delaware
Listed on
NYSE
Tickers
ABBV
Fiscal year end
12-31

Annual results

Fiscal year endedRevenueNet incomeTotal assets
2025-12-31$61.2B +8.6%$4.2B -1.2%$134B
2024-12-31$56.3B +3.7%$4.3B -12.0%$135B
2023-12-31$54.3B$4.9B$135B
As reported in each 10-K's XBRL data on SEC EDGAR (revenue tag Revenues); a later 10-K's restatement replaces the earlier figure.
FilingFiledPeriodAccession
Annual report (10-K)2026-02-202025-12-310001551152-26-000008
Quarterly report (10-Q)2026-11-032026-09-300001551152-26-000037
Current report (8-K)2026-11-022026-10-280001104659-26-121322

Filing activity

89 filings since 2025-11-21, 7 of them prospectus supplements and free writing prospectuses (not listed below). By form:

Form 4
44
8-K
17
Form 144
7
10-Q
3
10-K
1
11-K
1
Form 3
1
Form 4/A
1

8-K items in the last 12 months: results of operations (Item 2.02, 8) · other events (Item 8.01, 4) · officer or director changes (Item 5.02, 2) · Regulation FD disclosures (Item 7.01, 2) · shareholder vote results (Item 5.07, 1).

FiledFormDocumentPeriod
2026-11-184Form 4 insider filing2026-11-16
2026-11-16144Form 144 notice of proposed sale
2026-11-124Form 4 insider filing2026-11-09
2026-11-09144Form 144 notice of proposed sale
2026-11-0310-QQuarterly report2026-09-30
2026-11-028-KFORM 8-K2026-10-28
2026-10-308-KCurrent report on Form 8-K2026-10-30
2026-10-233Form 3 initial ownership filing2026-10-14
2026-10-158-KFORM 8-K2026-10-14
2026-10-058-KCurrent report on Form 8-K2026-10-05
free alert

Free. One email a day at most, only when something changes. Confirm by email first; unsubscribe with one click. Privacy.

The full due-diligence dossier on AbbVie Inc.

The free view above is the filing record: identity, annual results and the last year of filings. The paid dossier reads the filings: business and segments, financial trend, insider and institutional activity, litigation and risk-factor themes, recent news, and the red flags, every claim cited and delivered with a data appendix.

agents: POST /v1/dossier with {"ticker":"ABBV"} over x402 or MPP, $0.85

Sample output and API docsall reports

Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.